Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.
3.

Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.

Maciulis V, Bitter I, Milasiunas R, Dembinskas A, Radavicius L, Kaunas A, Dossenbach M, Walker D.

Curr Ther Res Clin Exp. 2004 Jan;65(1):57-69. doi: 10.1016/S0011-393X(04)90005-7.

4.

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.

Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.

Eur Psychiatry. 2007 Oct;22(7):433-43. Epub 2007 Jun 7.

PMID:
17555947
5.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115
6.

Practical issues with amisulpride in the management of patients with schizophrenia.

Pani L, Villagrán JM, Kontaxakis VP, Alptekin K.

Clin Drug Investig. 2008;28(8):465-77. Review.

PMID:
18598092
7.

Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial responders.

Altamura AC, Velonà I, Curreli R, Mundo E, Bravi D.

Int J Psychiatry Clin Pract. 2002;6(2):107-11. doi: 10.1080/136515002753724117.

PMID:
24931937
8.

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.

Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN.

J Clin Psychopharmacol. 1998 Aug;18(4):296-304.

PMID:
9690695
9.

An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.

Tamrakar SM, Nepal MK, Koirala NR, Sharma VD, Gurung CK, Adhikari SR.

Kathmandu Univ Med J (KUMJ). 2006 Apr-Jun;4(2):152-60.

PMID:
18603890
10.

A preliminary open trial of olanzapine in paediatric acute and transient psychotic disorders.

Agarwal V, Sitholey P.

Indian J Psychiatry. 2006 Jan;48(1):43-6. doi: 10.4103/0019-5545.31618.

11.

Amisulpride: a review of its use in the management of schizophrenia.

McKeage K, Plosker GL.

CNS Drugs. 2004;18(13):933-56. Review.

PMID:
15521794
12.

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG.

Arch Gen Psychiatry. 1997 Jun;54(6):549-57.

PMID:
9193196
13.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
14.

An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.

Hirschfeld RM, Eerdekens M, Kalali AH, Canuso CM, Khan AA, Karcher K, Palumbo JM.

Int Clin Psychopharmacol. 2006 Jan;21(1):11-20.

PMID:
16317312
15.

Olanzapine in the treatment of depression with psychotic features: A prospective open-label study.

Adli M, Wiethoff K, Baethge C, Pfennig A, Stamm T, Bauer M.

Int J Psychiatry Clin Pract. 2008;12(3):202-9. doi: 10.1080/13651500801911144.

PMID:
24931659
16.

Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study.

Kumar S, Chaudhury S.

Ind Psychiatry J. 2014 Jan;23(1):27-35. doi: 10.4103/0972-6748.144953.

17.

Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: a pilot randomized, open-label, comparative study.

Gobbi G, Comai S, Debonnel G.

Neuropsychiatr Dis Treat. 2014 May 7;10:757-65. doi: 10.2147/NDT.S59968. eCollection 2014.

18.

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation.

Anand E, Berggren L, Deix C, Tóth Á, McDonnell DP.

Neuropsychiatr Dis Treat. 2015 May 27;11:1349-57. doi: 10.2147/NDT.S79347. eCollection 2015.

19.

Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine.

Montgomery W, Kadziola Z, Ye W, Xue HB, Liu L, Treuer T.

Neuropsychiatr Dis Treat. 2015 Jan 19;11:177-83. doi: 10.2147/NDT.S73992. eCollection 2015.

20.

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians.

Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ, Hoffmann VP.

Patient Prefer Adherence. 2011;5:547-54. doi: 10.2147/PPA.S23255. Epub 2011 Nov 3.

Supplemental Content

Support Center